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ABSTRAK 
Latarbelakang: PenyaIdt Parkinson sering dikenali sebagai penyakit 'motor', tetapi ia 
juga mempunyai manifestasi bukan-motor seperti masalah kognitif. Masalah kognitif 
boleh memberikan kesan yang besar ke atas beberapa aspek penyakit ini. Masih belum 
terdapat kajian yang dilakukan berkenaan masalah kognitif dan penyakit Parkinson yang 
melibatkan populasi tempatan. 
Objektif: Untuk membuat perbandingan skor 'Unified Parkinson's Disease Rating Scale' 
(UPDRS) di antara pesakit yang mengalami masalah kognitif dan yang tidak mengalami 
masalah kognitif. Kedua, untuk menentukan prevalens masalah kognitif di kalangan 
pesakit-pesakit Parkinson yang menjalani rawatan susulan di Hospital Universiti Sains 
Malaysia (HUSM). 
Kaedah: Ini adalah kajian 'cross-sectional' yang dijalankan di Klinik Neurologi HUSM 
bermula dari lun hingga November 2006. Lapan puluh pesakit yang memenuhi kriteria 
kajian telah terlibat dalam kajian ini. Fungsi kognitif mereka telah di nilai menggunakan 
ujian 'Mini-Mental State' yang telah di sahkan ke dalam Bahasa Melayu. Skor ::; 24/30 
menandakan wujudnya masalah kognitif manakala skor > 24/30 adalah normal. 
Kemudian, semua pesakit telah menjalani ujian menggunakan UPDRS. UPDRS 
mengandungi 4 item iaitu keadaan mental, kelakuan, dan perasaan; aktiviti harian, 
pemeriksaan fungsi motor, dan komplikasi rawatan. Skor diambil dari setiap item, dan 
Xl 
kemudian di cam pur untuk mendapatkan jumlah skor. Protokol untuk kajian ini telah 
disemak dan diluluskan oleh lawatankuasa Etika dan Penyelidikan USM. 
Keputusan: Tiga puluh dua (40%) pesakit telah dikesan mempunyai masalah kognitif, 
dari peringkat sedikit hingga teruk, berdasarkan ujian MMSE. Pesakit-pesakit yang 
mempunyai masalah kognitif mempunyai skor yang lebih teruk untuk setiap item UPDRS 
berbanding pesakit-pesakit yang tidak mengalami masalah kognitif (p < 0.05). Mereka 
juga mempunyai skor yang lebih teruk untuk tahap kekerasan anggota badan dan 
kelambatan pergerakan aggota badan (p < 0.05). Setelah mempertimbangkan faktor-
faktor seperti umur pesakit dan tempoh mengalami penyakit Parkinson, didapati skor 
UPDRS masih lebih teruk bagi pesakit yang mengalami masalah kognitif (p < 0.05). 
Kesimpulan: Kajian ini telah menunjukkan bahawa masalah kognitif menyebabkan skor 
UPDRS menjadi lebih teruk. Ramai pesakit Parkinson yang menjalani rawatan susulan di 
HUSM mengalami masalah kognitif. Oleh sebab itu, pesakit-pesakit Parkinson perlu 
menjalani ujian seringan yang kerap untuk mengesan masalah kognitif. 
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ABSTRACT 
Background: Parkinson's disease (PD) is widely known as a 'motor' disease, but it also 
has several non-motor features including cognitive impairment. Cognitive impairment has 
significant impacts on several aspects of PD. There is as yet a study on cognitive 
impairment and PD done involving our population. 
Objectives: To compare the Unified Parkinson's Disease Rating Scale (UPDRS) score 
between PD patients with and without cognitive impairment. Secondly, to determine the 
prevalence of cognitive impairment in patients with PD under Hospital Universiti Sains 
Malaysia (HUSM) follow-up. 
Methods: This was a cross-sectional study done at the HUSM Neurology Clinic, 
beginning from June till November 2006. Eighty PD patients who satisfied the study 
criteria were recruited into the study. Their cognitive status was assessed using the 
validated Malay version of the Mini-Mental State Examination (MMSE). A score of :S 
24/30 signified presence of cognitive impairment while> 24/30 was normal. Regardless 
of their MMSE scores, all the patients then underwent assessment using the UPDRS. The 
UPDRS contains four items i.e. mentation, behaviour, and mood; activities of daily 
living; motor examination; and complications of therapy. Scores were taken from each 
item, and they were then totaled to obtain a total score. The study protocol was reviewed 
and approved by the USM Ethics and Research Committee. 
Results: Thirty two patients (40%) had cognitive impairment, ranging from mild to 
severe, based on the MMSE. Patients with cognitive impairment had significantly worse 
Xll1 
scores for each UPDRS item compared to the non-cognitive impairment group (p < 0.05). 
They also had worse rigidity and bradykinesia compared to the other group (p < 0.05). 
After adjusting for potential confounders e.g. age and disease duration, the cognitive 
impairment group still performed worse in the UPDRS assessment (p < 0.05). 
Conclusions: The study showed that the presence of cognitive impairment resulted in 
worse UPDRS scores. There was a high prevalence of cognitive impairment in PD 





1.1 General Consideration 
Parkinson's disease (PD) is now increasingly recognized as a chronic progressIve 
neuropsychiatric disorder. It is predominantly a disease of the elderly, affecting those 
over 50 years of age. It is a multisystem neurological disorder which affects cognitive 
process, emotion and autonomic function. It is the second most common cause of chronic 
neurological disability in the UK. 
Management of PD, therefore, should address all the aspects involved as a result of its 
multisystemic nature. PD patients' quality of life (QOL) depends not only on the stage of 
the disease but also on the level of depression, optimism, and satisfaction (Global 
Parkinson's Disease Survey). At the Sixth International Congress of Parkinson's Disease 
and Movement Disorders in June 2000, many presenters confirmed that the effects of 
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treatment on QOL are dependent upon factors other than the quality of movement. 
Factors such as cognitive impairment, depression, disability and postural instability seem 
to have the greatest influence on QOL in PD (Schrag et al. 2000). PD has a marked effect 
on QOL at all stages of the disease, and at all ages. Impaired QOL and carer strain 
increase with advancing disease and age (Findley et al. 2000). The total costs of the 
condition increase with advancing age and advancing disease stage. In younger patients 
the greatest costs are for the drugs and loss of earnings, while in older patients the largest 
the largest costs are social and long-term institutional care. These cost burdens fall on 
patients, carers, health and social agencies (MacMahon et al. 2000) 
At present there is no local data or literatures that look at different aspects of PD in the 
community. This study was designed in the hope that it could examine a few aspects of 
PD in this community, and that it would trigger more research involving our own PD 
patients in the future. 
1.2 Definitions 
1.2.1 Parkinsonism 
Making a proper diagnosis of PD is quite challenging because PD has many imitators. A 
patient who presents with bradykinesia, rigidity and tremor does not necessarily have PD. 
In fact, these symptoms only suggest a clinical syndrome called parkinsonism. The causes 
of parkinsonism can be classified into three major groups: (i) PD~ (ii) atypical 
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parkinsonian syndromes (parkinsonism plus) and other neurodegenerative disorders; and 
(iii) secondary or symptomatic causes e.g. drug-induced or cerebrovascular related. PD 
remains the most common cause of parkinsonism at all ages. However, the prevalence of 
the atypical parkinsonism, drug-induced parkinsonism, cerebrovascular-related 
parkinsonism also increases with advancing age. 
Despite the similarities in the main clinical presentation, there are useful atypical features 
which can differentiate PD from other diagnoses. Presence of early dementia in the course 
of the disease, early falls and postural instability, severe autonomic dysfunction, poor or 
transient benefit from drug treatment, striking asymmetry of motor signs, absence of rest 
tremor may suggest diagnoses other than PD (Rotnitzky 2000). 
A correct diagnosis is vital because management and outlook differ between PD and 
parkinsonian-like syndromes. Misdiagnosis may result in fruitless treatment with 
dopaminergic drugs, which may produce neuropsychiatric side effects especially in 
susceptible older subjects. 
1.2.2 Parkinson's Disease 
PD has characteristic clinical features and natural history. It is recognized as levodopa-
responsive parkinsonism. Pathologically, it shows degeneration of cells in substantia 
nigra, resulting in striatal dopamine deficiency and the presence of surviving cells of 
inclusions called Lewy bodies. 
3 
There is no precise clinical definition ofPD yet, but most experts consider the presence of 
two or more cardinal motor signs (one of which must include bradykinesia) and a 
consistent response to levodopa as indicative of PD. Asymmetric onset is a strong 
indicator ofPD (Hughes 1992). 
1.3 Epidemiology 
Epidemiological studies describe PD in terms of prevalence, incidence, mortality, and the 
natural history of the disease. Epidemiological reports vary between centers, and the 
variation could be due to different methods used in studies e.g. different diagnostic 
criteria used. 
1.3.1 Prevalence 
PD affects all races and has a fairly uniform worldwide distribution, though the 
prevalence in Africa, China and Japan has reduced (Zhang 1993). Differences in 
prevalence between racial groups may reflect differing environmental rather than genetic 
factors (Jendroska 1994). Studies around the world based on all ages suggest a prevalence 
of 120 per 100 000 population. 
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1.3.2 Incidence 
The crude incidence of PD world-wide is estimated between 2 and 24 cases per 100 000 
per year (Morens 1996). Obviously, the incidence rises with age, and is greatest in the 
eighth decade of life (Zhang 1993). Limited data suggest that the annual incidence is 
significantly higher in men than women (Zhang 1993). 
1.3.3 Mortality 
It used to be that PD patients were three times more likely to die compared to their peers 
(Hoehn 1967). This occurred prior to the introduction of levodopa therapy. However, 
several studies from around the world indicate that mortality is still at least doubled in PD 
despite drug treatment (Bennet 1996). People aged over 70 years who have PD are 
significantly more likely to die than their peers (Bennet 1996). Those whose disease has 
been present for more than 10 years (Morens 1996), and those with gait disturbance 
(Bennet 1996), may be more likely to die than their peers. However, these latter findings 
were not confirmed in other studies. 
1.3.4 Malaysian data 
There is no published data on PD from Malaysia. Generally, however, the prevalence is 
estimated at 160 per 100 000 population (Jusoh MR, 2000). The number of new cases 
attending the neurology clinic in Hospital Kuala Lumpur was 91 in 1998, and increased to 
107 in 1999. It is estimated that 3% of all new cases is made up of PD patients. These 
figures are likely to increase in the future as people understand more about this disease. 
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1.4 Aetiology 
The cause of PD is unclear in the majority of cases. However, various studies have 
suggested possible causes such as: 
1.4.1 Genetics 
Researchers have found that a mutation in alpha-synuclein gene in a few Greek and 
Italian families that appear to cause a dominantly transmitted form of PD (Golbe et.a/ 
1990; Polymeropoulis et af. 1997). Another gene, Parkin, may be the causal factor in 
some young onset « 40 years) and juvenile onset « 20 years) parkinsonian patients, and 
may also playa role causing susceptibility in individuals of typical age (50's) or later age 
of onset of symptoms (Kitada et al. 1998; Jarman 1999). It is likely that the onset of 
symptoms of PD in individuals younger than the age of 50 years is related to a 
combination of genetic and toxic factors. 
1.4.2 Environmental toxins 
In the 1980's, a number of drug addicts developed symptoms similar to those ofPD after 
injecting a synthetic narcotic known as I-methyl-4phenyl 1,2,3,6 tetrahydropyridine 
(MPTP). MPTP is a toxin than can destroy dopamine neurons in the substantia nigra. 
1.4.3 Welder's exposure 
Some preliminary data exist that suggest that individuals who experience exposure to 
manganese in the fumes from welding rods may be at higher risk than the general 
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population to develop PD. It appears that this exposure leads to a younger age of onset of 
symptoms (approximately 46 years old) than the general population (Racette et ale 2005). 
1.5 Diagnosis 
1.5.1 Diagnostic criteria 
A number of diagnostic criteria for PD have been formulated which usually require the 
presence of cardinal signs (rigidity, bradykinesia, tremor) in association with exclusionary 
and supportive features (Gelb et ale 1999). There is no ideal criteria yet established 
because of the clinical variability in pathologically confirmed PD (Hughes et al. 1993). 
Levodopa responsiveness and dyskinesia are supportive features for PD in most criteria, 
yet 2% of autopsy-proven cases show a poor or absent response to levodopa (Hughes et 
ale 1993). Conversely, a positive response is not specific to PD. Patients with progressive 
supranuclear palsy and multiple system atrophy (MSA) may show an initial response to 
levodopa. 
At present, neuropathological brain examination in conjunction with clinical history is the 
'gold standard' for diagnosis of PD. The United Kingdom (UK) Parkinson's Disease 
Society Brain Bank (UKPDSBB) clinical diagnostic criteria are now the most widely 
accepted criteria for the diagnosis of PD (Litvan et al. 2003). Bradykinesia is required, 
plus the presence of rigidity, rest tremor or postural instability. Three or more supportive 
criteria and absence ofa list of 16 exclusion criteria are required (Appendix A). 
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1.5.2 ,Neuroimaging and neurophysiologic studies 
The differentiation of PD from other causes of parkinsonism is largely based on careful 
clinical observation and examination. In some instances, however, neuroimaging or 
neurophysiologic studies may enhance the certainty of the clinical diagnosis. 
Neuroimaging studies are almost never of significant benefit in confirming a diagnosis of 
PD. Neither the magnetic resonance imaging (MRI) of the head nor computed 
tomography (CT) of the head, reveal any consistent findings. Subtle abnormalities are 
sometimes found in the region of the substantia nigra in MRI of the brain in late stage of 
PD (Stern et al. 1989) but they are not sufficiently common or definitive to be of great 
practical benefit in everyday practice. Similarly, neurophysiologic tests such as 
electroencephalogram (EEG), evoked potentials, and blink reflex studies, while revealing 
subtle abnormalities, are seldom useful in establishing a diagnosis of PD. Neuroimaging 
is occasionally useful in evaluation of patients with other forms of degenerative 
parkinsonism. The primary rationale behind obtaining a neuroimaging study in a patient 
with parkinsonism is not to confirm the diagnosis of PD, but to determine if a 
multisystem degenerative or vascular form of parkinsonism is present (Anouti and Koller 
1996). 
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1.6 Clinical Features 
As described earlier, the diagnosis of PD remains entirely clinical. There are no discrete 
biological markers available to confirm diagnosis. Some investigations are useful in 
recognizing other causes of parkinsonism. To establish a diagnosis of PD (or other 
parkinsonian syndromes), a two-step process is required. Firstly, one needs to confirm the 
presence of true parkinsonism by clinical examination. Secondly, whether it is PD or 
other parkinsonian syndromes, will depend on the presence of other clinical features, 
progression of the disease and response to treatment. This requires regular clinical review 
of the patient. 
The four cardinal features ofPD are described below. 
1.6.1 Bradykinesia 
A generalized slowness of movement is arguably the defining feature of PD and other 
parkinsonian disorders. This is a major cause of disability in PD. Patients usually notice a 
delay in the initiation of voluntary movement, with difficulty multitasking or executing 
sequential actions. Family members will first notice a decrease of spontaneous associated 
movements, such as loss of gestures during conversation, decreased eye blinking or facial 
masking. The voice may become softer (hypophonia), with the patient frequently needing 
to repeat sentences. Bradykinesia of the pharyngeal musculature leads to pooling of saliva 
in the mouth and drooling, even though normal amount of saliva produced. 
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Assessment of bradykinesia in elderly can be a challenge. Slowing of motor performance 
is common with advancing age (van Hilten et al. 1995). However, age-related slowing is 
usually symmetrical and does not show the marked fatigability that defines true 
bradykinesia. Other diseases of peripheral and central nervous systems as well as focal 
pathology such as arthritis may also simulate bradykinesia. Therefore, meticulous clinical 
assessment remains the principal tool in distinguishing imitators from PD. 
1.6.2 Rigidity 
Rigidity is a hypertonic state and is defined as an increase in resistance to passive 
movements around a joint. The 'cogwheel' rigidity particularly occurs in PD, and is 
thought to be tremor superimposed on rigidity. 'Lead pipe' rigidity, which can also occur 
in PO, is smooth throughout the entire range of motion. 
Rigidity or cog wheeling may not be detectable on routine testing, but Froment's 
manoeuvre may be helpful in unmasking the abnormality. Rigidity may be elicited when 
the contralateral limb is activated e.g. drawing a circle in the air, making a fist. 
Asymmetrical augmentation of tone with cogwheeling is suggestive of PD. PO can also 
affect axial musculature and contributes to the postural deformities seen in PD. 
A mild increase in tone may occur in healthy elderly persons, so caution in interpretation 
is necessary in some cases. 
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